Truist upgraded Globus Medical (GMED) to Buy from Hold with a price target of $93, up from $65. The firm has greater confidence in the company’s mid- to high-single-digit revenue growth outlook with low- to mid-teens earnings growth. Nevro accretion is getting pulled forward nearly one year ahead of expectations while Globus is seeing accelerating trends in the core spine business, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED: